Organogenesis's Q2 2026 Earnings Call: Dermagraph Timeline Delay, Revenue Guidance Confidence Shifts Highlight Contradictions

Date of Call: Aug 6, 2026

Financials Results

• Revenue: $42.8M net product revenue, down 58% YOY
• Gross Margin: 45% of net product revenue, compared to 73% last year (49% on a non-GAAP basis)

Guidance:

• Full-year 2026 total net revenue expected to be $179M to $215M, representing a decline of 62% to 68% YOY (prior guidance was decline of 45% to 52%).
• Expect sequential improvement in revenue trends in Q3 and Q4, but at a more measured pace.
• Expect nearly 60% reduction in adjusted EBITDA loss in H2 vs. H1 at low end of range, with positive adjusted EBITDA in Q4.
• Operating expenses, excluding COGS, expected to decrease ~32% YOY in 2026, with >40% decrease in H2.

Business Commentary:

Revenue Decline and Market Contraction:

• Organogenesis Holdings reported a 58% year-over-year decline in total revenue, primarily driven by a 61% decrease in advanced wound care product sales.
• The significant contraction is attributed to actions and comments from CMS in late December 2025, which have impacted the skin substitute market.

Sequential Improvement and Strategic Adjustments:

• Net product revenue increased 18% quarter-over-quarter in Q2, driven by a 23% increase in advanced wound care product sales.
• The company made strategic decisions, including a workforce reduction of 138 employees, to reduce costs and better position itself for future success amid a prolonged recovery.

Outlook and Financial Guidance:

• The company updated its 2026 total revenue guidance to a decline range of 62% to 68% year-over-year, down from a previous expectation of a 45% to 52% decline.
• This adjustment reflects a more measured pace of recovery in the skin substitute market, impacting revenue expectations for the third and fourth quarters.

Product Development and Regulatory Progress:

• The FDA accepted the biologic license application for MNUVICs, with a PDUFA target action date of April 24, 2027.
• This represents a transformational opportunity for the company, establishing a new market category for a biologic product in knee osteoarthritis treatment.

Operational Challenges and Cost Management:

• Operating expenses were reduced by 17% year-over-year, with non-GAAP operating expenses decreasing by 25%.
• The cost reduction was driven by a focus on improving profitability amid a challenging operating environment, including non-recurring termination costs in R&D.

Sentiment Analysis:

Overall Tone: Neutral

• Management expressed optimism about long-term market position and new opportunities (e.g., 'I remain very optimistic about our future' and 'we believe we are best positioned'). However, they acknowledged significant near-term challenges, including revenue declines, a more measured recovery outlook, and the need for restructuring, stating 'our 2026 revenue guidance now reflects the expectation that we see a more measured pace of recovery' and 'we have updated our expectations...subsequent to quarter end.'

Q&A:

• Question from Ryan Zimmerman (U.S. Bancorp): I just want to start to get kind of your higher level thoughts on the broader market dynamics and what is going to give you confidence that Medicare is working to stabilize the market beyond just what we've seen in the OPPS proposal?
  Response: Management cites month-over-month growth, clinicians becoming more comfortable with current coverage/payment structure, CMS reinstating reimbursement rates and maintaining tier structure to bring stability, and a 'flight to quality' favoring products with clinical evidence as reasons for confidence in stabilization.

• Question from Ryan Zimmerman (U.S. Bancorp): As we start to think about the back half of the year, I was hoping you could speak a little bit more about the pacing that's baked into guidance for third quarter and fourth quarter.
  Response: Guidance expects continued modest sequential growth and share gains, but more modest than Q2's 30% unit volume increase, with slightly more strength anticipated in Q4 than Q3.

• Question from Ryan Zimmerman (U.S. Bancorp): Could either of you speak to what products are actually being paid for versus what might be held up in the market, whether it's synthetics, amniotics, anything you can provide there?
  Response: Management sees no particular product held up, but notes clinicians are concerned about potential clawbacks for products lacking RCT evidence, leading to a 'flight to quality' and market share gains for evidence-based products like theirs.

• Question from Ravi Misra (Truist): Can you help us understand kind of what gives you comfort to get you know, what are the kind of the puts and takes that get us to the low end or the high end of the guide?
  Response: The low end of guidance is based on current growth but slightly less than the strong sequential growth seen in Q2. The high end assumes current growth plus a small market expansion by late Q3/Q4.

• Question from Ravi Misra (Truist): Just on Dermagraph, still on your cue that you're kind of shelving that for now, can we talk about the opportunity there that you're maybe stepping away from or the thinking around when that does come back to market and the rationale for why?
  Response: Manufacturing build-out for Dermagraph is being slowed to preserve cash, which will delay its launch by about a year to mid-2028, with no significant revenue expected in 2027.

• Question from Ravi Misra (Truist): Just help us think about maybe how you see this slotting into the competitive landscape if and when approved.
  Response: MNUVIC, if approved, would be the first biologic in its space with a unique place, strong clinical/safety data, and expected significant ramp post-launch with a temporary code until permanent code is secured in late 2027/early 2028.

Contradiction Point 1

Dermagraph Product Launch Timeline

Inconsistent messaging on the timing of the Dermagraph product launch.

Ryan Zimmerman (U.S. Bancorp) - Ryan Zimmerman (U.S. Bancorp)

2026Q2: Gary clarified that no specific product is being held up... Products without RCTs are often considered investigational, and this concern is driving the market share gains for Organogenesis's evidence-based products. - Gary S. Gilheny, Sr.(CEO)

What gives confidence in Medicare's ability to stabilize the market beyond the OPPS proposal, what is the expected pacing for revenue recovery in the back half of the year, and which products are currently being paid for versus those facing delays? - Ravi Misra (Truist)

2026Q2: Gary stated that the launch of Dermagraph is still expected, but the manufacturing build-out is being slowed to preserve cash, delaying the launch by approximately one year. The original launch target was mid-2027, and it is now expected around mid-2028. - Gary S. Gilheny, Sr.(CEO)

Contradiction Point 2

Confidence Level in Revenue Guidance Range

Contradiction on which end of the guidance range the company is more confident in.

Ravi Misra (Truist) - Ravi Misra (Truist)

2026Q2: Gary explained the low end of the guidance range reflects a more conservative view... The high end assumes continuation of current growth trends... The company has more confidence in the low end. - Gary S. Gillheeney, Sr.(CEO)

What gives comfort for the guidance range (low vs. high end), how should we think about sequential volume growth into Q3 and Q4, and what is the update on the Dermagraph product? - Ravi Misra (Truist Securities)

2026Q2: Gary explained the low end of the guidance range reflects a more conservative view, assuming growth slightly less than the 30% seen in Q2. The high end assumes continuation of current growth trends with a small market expansion by late Q3/Q4. - Gary S. Gilheny, Sr.(CEO)

Contradiction Point 3

Timeline for CMS Policy Clarity

Inconsistent statements on when CMS will provide clarity on wastage policies.

Ryan Zimmerman (U.S. Bancorp) - Ryan Zimmerman (U.S. Bancorp)

2026Q2: Gary stated that month-over-month growth is occurring... CMS has reinstated the 127.14 reimbursement rate to stabilize the market, and the tier structure recognizing PMA products is bringing stability. - Gary S. Gilheny, Sr.(CEO)

What gives confidence in Medicare's ability to stabilize the market beyond the OPPS proposal, what is the pacing for revenue recovery in the back half of the year, and which products are being paid for versus held up in the market? - Izzy (Analyst, BTIG) (on behalf of Ryan Zimmerman)

2026Q1: There is currently no clarity on a timeline for CMS to provide updates or clarify their wastage policy comments. - Gary S. Gillheeney Sr.(CEO)

Contradiction Point 4

Pacing of Revenue Recovery

Conflicting guidance on the expected speed of market recovery in the back half of 2026.

Ryan Zimmerman (U.S. Bancorp) - Ryan Zimmerman (U.S. Bancorp)

2026Q2: David noted that after a 30% sequential unit volume increase from Q1 to Q2, the guidance assumes more modest sequential growth in Q3 and Q4, with continued share gains but less rapid recovery than initially expected. - David Francisco(CFO)

What gives confidence that Medicare is working to stabilize the market beyond the OPPS proposal, and what is the pacing for revenue recovery in the back half of the year and which products are being paid for versus held up in the market? - Izzy (Analyst, BTIG) (on behalf of Ryan Zimmerman)

2026Q1: Confidence is based on several factors: 1) Sequential monthly improvement continued into April, 2) Expectation that customer confusion will abate as the year progresses, and 3) Anticipated changes in competitive dynamics. The forecast is built on the expectation of sequential quarterly revenue growth throughout the year. - Dave Francisco(CFO)

Contradiction Point 5

Competitive Landscape and Product Launch Timeline

Outlook on competitive pressure and product launch timing changes significantly.

Ravi Misra (Truist) - Ravi Misra (Truist)

2026Q2: The manufacturing build-out is being slowed to preserve cash, delaying the launch by approximately one year. The original launch target was mid-2027, and it is now expected around mid-2028. - Gary S. Gilheny, Sr.(CEO)

What gives comfort for the guidance range, how should we think about sequential volume growth into Q3 and Q4, and what is the update on the Dermagraph product? - Iseult McMahon (Analyst for Ryan Zimmerman, BTIG)

20260227-2025 Q4: The company believes the flood of low-cost products is transitory and that competitive dynamics will improve. ... Early signs include aggressive pricing pressure as competitors try to clear inventory. - Gary Gillheeney(CEO), David Francisco(CFO)